文献速递类风湿关节炎

超声在无临床滑膜炎的抗CCP抗体阳性高危个体中的应用:开发可行的6关节风险预测方案

Ultrasound in anti-CCP+ at-risk individuals without clinical synovitis: development of a novel 6-joint protocol for feasible risk prediction.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在417例无临床滑膜炎的抗CCP抗体阳性高危个体中,基线36关节超声评估滑膜炎和骨侵蚀,随访至少24个月。24个月时92/417(22.1%)发展为炎性关节炎。包含36关节超声的临床-超声扩展模型预测效能优于仅临床模型(AUC 0.788 vs 0.731,P<0.001)。保留腕、膝和第五跖趾关节的6关节简版方案预测效能与扩展模型相似。

要点

  • 超声滑膜炎与炎性关节炎发展风险增加约3倍相关(OR 3.18,95%CI 1.80-5.63)。
  • 骨侵蚀与炎性关节炎发展风险增加约2.5倍相关(OR 2.54,95%CI 1.21-5.37)。
  • 6关节简版超声方案预测效能与36关节扩展方案相似,临床可行。

核心结论

  • 超声无论单独使用还是联合临床变量,均为预测抗CCP抗体阳性个体进展为炎性关节炎提供有价值的信息。
  • 超声滑膜炎与炎性关节炎发展风险增加约3倍相关。
  • 6关节简版超声方案可在抗CCP抗体阳性高危个体中提供临床可行的风险预测。

研究设计与样本

  • 在417例有肌肉骨骼症状但无临床滑膜炎的抗CCP抗体阳性高危个体(Leeds CCP队列)中收集人口学和临床数据,基线行36关节超声评估滑膜炎和骨侵蚀,随访至少24个月。
  • 采用多变量二元回归模型评估24个月时炎性关节炎发展,分别构建仅含常规临床变量的临床模型、联合36关节超声的临床-超声扩展模型以及临床-超声简版模型。

主要发现

  • 24个月时92/417(22.1%)抗CCP抗体阳性高危个体发展为炎性关节炎,中位时间7个月(四分位距3-12)。
  • 临床-超声扩展模型预测效能优于临床模型(AUC 0.788 vs AUC 0.731,P<0.001)。
  • 超声滑膜炎预测炎性关节炎发展的OR为3.18(95%CI 1.80-5.63),骨侵蚀OR为2.54(95%CI 1.21-5.37)。
  • 保留腕、膝和第五跖趾关节的临床-超声简版模型预测效能优于临床模型(AUC 0.782,P<0.001),且与临床-超声扩展模型相似(赤池信息准则差异<2)。

关键数值与推荐

  • 临床-超声扩展模型AUC 0.788 vs 临床模型AUC 0.731(P<0.001)。
  • 超声滑膜炎OR 3.18(95%CI 1.80-5.63),骨侵蚀OR 2.54(95%CI 1.21-5.37)。
  • 临床-超声简版模型AUC 0.782,与临床模型比较P<0.001,与扩展模型赤池信息准则差异<2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate, in anti-CCP antibody-positive individuals with musculoskeletal symptoms but no clinical synovitis (CCP+ at-risk), the additional value of US for the prediction of inflammatory arthritis. Furthermore, to define a concise US protocol for feasible risk prediction. METHODS: Demographic and clinical data were collected in 417 CCP+ at-risk (Leeds CCP cohort) with a baseline US scan assessing synovitis and bone erosions in 36 joints, and a follow-up duration ≥24 months. Multivariable binary regression models for inflammatory arthritis development at 24 months evaluated routine clinical variables associated with inflammatory arthritis alone ('clinical' model) and combined with a 36-joint US scanning protocol ('clinical-US extended' model). A 'clinical-US short' model was also developed. RESULTS: At 24 months, 92/417 (22.1%) CCP+ at-risk developed inflammatory arthritis (median time 7 months, interquartile range 3-12). The 'clinical-US extended' model performed better than the 'clinical' model [area under the curve (AUC) 0.788 vs AUC 0.731, respectively, P < 0.001] with an odds ratio for inflammatory arthritis development of 3.18 (95% CI 1.80-5.63) for US synovitis and 2.54 (95% CI 1.21-5.37) for bone erosions. The 'clinical-US short' model, which retained the wrists, knees and MTP5 joints, performed better (AUC 0.782) than the 'clinical' model (P < 0.001) and similarly (difference in Akaike information criteria <2) to the 'clinical-US extended' model. CONCLUSIONS: US provides valuable information for predicting progression to inflammatory arthritis in CCP+ individuals both alone and in addition to clinical variables. US synovitis was associated with a 3-fold increase risk of inflammatory arthritis development. A concise US protocol of six joints provides clinically feasible risk prediction in CCP+ at-risk.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Di Matteo A, De Lorenzis E, Duquenne L, et al. Ultrasound in anti-CCP+ at-risk individuals without clinical synovitis: development of a novel 6-joint protocol for feasible risk prediction. Rheumatology (Oxford). 2024. PMID: 37934127. doi:10.1093/rheumatology/kead570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。